Shares of Pharming Group NV (PHAR) jumped over 6% on Tuesday. The biopharmaceutical company's 2026 financial guidance exceeded analyst expectations. Despite a recent setback for its Joenja treatment, Pharming projected total revenue between $405 million and $425 million, representing 8% to 13% growth.
This positive outlook signals investor confidence in the company's future.
Source: Investing.com · Summarized by HeadlinesBriefing